Your browser doesn't support javascript.
loading
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho, Nicole L; Marx, Wolfgang; Gonzalez, Maria; Sinclair, Justin; de Manincor, Michael; Perkins, Daniel; Sarris, Jerome.
Afiliação
  • Galvão-Coelho NL; Laboratory of Hormone Measurement, Department of Physiology and Behavior, Federal University of Rio Grande do Norte, Natal, RN, Brazil. nicolelgalvaocoelho@gmail.com.
  • Marx W; Postgraduate Program in Psychobiology and Department of Physiology and Behavior, Federal University of Rio Grande do Norte, Natal, RN, Brazil. nicolelgalvaocoelho@gmail.com.
  • Gonzalez M; National Institute of Science and Technology in Translational Medicine, São Paulo, Brazil. nicolelgalvaocoelho@gmail.com.
  • Sinclair J; NICM Health Research Institute, Western Sydney University, Westmead, Australia. nicolelgalvaocoelho@gmail.com.
  • de Manincor M; Departamento de Fisiologia e Comportamento, Universidade Federal do Rio Grande do Norte, Caixa Postal, 1511, CEP: 59078-970, Natal, RN, Brasil. nicolelgalvaocoelho@gmail.com.
  • Perkins D; IMPACT Research Institute, School of Medicine, Deakin University, Geelong, Australia.
  • Sarris J; NICM Health Research Institute, Western Sydney University, Westmead, Australia.
Psychopharmacology (Berl) ; 238(2): 341-354, 2021 Feb.
Article em En | MEDLINE | ID: mdl-33427944
RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option. OBJECTIVE: We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy and clinical populations (separately). RESULTS: Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium (2-7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms. CONCLUSION: Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Agonistas do Receptor de Serotonina / Transtornos do Humor / Transtorno Depressivo Maior / Alucinógenos Tipo de estudo: Clinical_trials / Diagnostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Psychopharmacology (Berl) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Agonistas do Receptor de Serotonina / Transtornos do Humor / Transtorno Depressivo Maior / Alucinógenos Tipo de estudo: Clinical_trials / Diagnostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Psychopharmacology (Berl) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Alemanha